The discovery of mutations in BRAF (B-Raf proto-oncogene, a serine/threonine kinase) and EGFR (epidermal growth factor receptor) by DNA sequencing contributed to the development of new targeted therapies for liver cancer patients carrying these mutations [6, 7]. The gene discussed is EGFR; the disease is liver cancer.